MNK

Mitogen activated protein kinase interacting kinase; MAP kinase interacting kinase; MAPK interacting kinase

Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogene eIF4E on serine 209. This phosphorylation has been reported to be required for its oncogenic activity. Eukaryotic initiation factor 4E (eIF4E) is a key component of the translational machinery and an important modulator of cell growth and proliferation. The activity of eIF4E is thought to be regulated by interaction with inhibitory binding proteins (4E-BPs) and phosphorylation by mitogen-activated protein (MAP) kinase-interacting kinase (MNK) on Ser209 in response to mitogens and cellular stress.

MNK Inhibitors

Cercosporamide
((-)-Cercosporamide) Cat. No.: HY-16982

Cercosporamide is a highly potent, ATP-competitive **Pkc1** kinase inhibitor, with an IC_{50} of <50 nM and a K_i of <7 nM. Cercosporamide is a unique **Mnk** inhibitor.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

CGP 57380
Cat. No.: HY-10520

CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of **Mnk1** with IC_{50} of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ETC-206
Cat. No.: HY-112424

ETC-206 is a selective **MNK1** and **MNK2** inhibitor with IC_{50}s of 64 nM and 86 nM, respectively.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

K783-0308
Cat. No.: HY-115906

K783-0308 is a potent and selective dual inhibitor of **FLT3** and **MNK2** with IC_{50} values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC_{50}=10.5 μM) and MV-4-11 (IC_{50}=10.4 μM) cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MNK1/2-IN-5
Cat. No.: HY-139684

MNK1/2-IN-5 is a potent and selective **MNK1/2** inhibitor as a therapeutic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MNK1/2-IN-6
Cat. No.: HY-146735

MNK1/2-IN-6 is a potent and selective **MNK1/2** inhibitor with IC_{50}s of 2.3 nM and 3.4 nM for MNK1 and MNK2, respectively. MNK1/2-IN-6 induces **apoptosis** in a concentration-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

QL-X-138
Cat. No.: HY-124645

QL-X-138 is a potent and selective **BTK/MNK dual kinase** inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC_{50}s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SLV-2436
(SEL201-88; SEL-201) Cat. No.: HY-112113

SLV-2436 is a highly potent and ATP-competitive inhibitor of **MNK1** and **MNK2** with IC_{50}s of 10.8 nM and 5.4 nM, respectively.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tomivosertib
(eFT508) Cat. No.: HY-100022

Tomivosertib (eFT508) is a potent, highly selective, and orally active **MNK1** and **MNK2** inhibitor, with IC_{50}s of 1-2 nM against both isoforms.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg